EJXB Stock Overview
A medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Elekta AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.46 |
| 52 Week High | SEK 7.50 |
| 52 Week Low | SEK 4.03 |
| Beta | 1.09 |
| 1 Month Change | -0.80% |
| 3 Month Change | -15.37% |
| 1 Year Change | -39.15% |
| 3 Year Change | -36.63% |
| 5 Year Change | -46.93% |
| Change since IPO | 107.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| EJXB | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.4% | -0.7% |
| 1Y | -39.2% | -14.3% | 15.2% |
Return vs Industry: EJXB underperformed the German Medical Equipment industry which returned -14.3% over the past year.
Return vs Market: EJXB underperformed the German Market which returned 15.2% over the past year.
Price Volatility
| EJXB volatility | |
|---|---|
| EJXB Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: EJXB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: EJXB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 4,536 | Jonas Bolander | elekta.com |
Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software.
Elekta AB (publ) Fundamentals Summary
| EJXB fundamental statistics | |
|---|---|
| Market cap | €1.74b |
| Earnings (TTM) | €21.73m |
| Revenue (TTM) | €1.65b |
Is EJXB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EJXB income statement (TTM) | |
|---|---|
| Revenue | SEK 18.02b |
| Cost of Revenue | SEK 11.21b |
| Gross Profit | SEK 6.81b |
| Other Expenses | SEK 6.57b |
| Earnings | SEK 237.00m |
Last Reported Earnings
Apr 30, 2025
Next Earnings Date
Jul 04, 2025
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 37.80% |
| Net Profit Margin | 1.32% |
| Debt/Equity Ratio | 72.0% |
How did EJXB perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/03 17:40 |
| End of Day Share Price | 2025/06/02 00:00 |
| Earnings | 2025/04/30 |
| Annual Earnings | 2025/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elekta AB (publ) is covered by 36 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Sumit Sayal | AlphaValue |
| Alexander Kleban | Barclays |